Personalized Immune Cell Treatment NKCL Classic
NKCL Bio Group Inc. (hereinafter referred to as ‘NKCL Bio Group’) is a Korean Bio Group company that researches and develops NK Immune cell treatment which utilizes NK immune cells. With its competitive technologies including cancer cell target treatment and Automatic NK Cell Cultivation System, NK...
On March 13, Chairman Shin Dong-hwa of NKCL Bio Group signed a MOU with CYBERJEK, an Indonesian car sharing service app company, to launch the NK immune care service in Indonesia. CYBERJEK is an O2O platform that provides delivery and taxi services using the app, and has 80,000 biker members and 200,...
NKCL Bio group Inc. (hereinafter referred to as NKCL Bio Group) is a Korean bio company that researches and develops NK immune cell treatment using NK immune cell with its competitive technology. Last year, it had laid the foundation for popularizing NK immune cell treatment by opening the constructi...
Source: [Medical Observer] http://www.monews.co.kr/news/articleView.html?idxno=207654 “Enforcement ordinance for Advanced Regenerative Bio Law will be prepared in February” “We need to move beyond the bio-similar to the original developing phase”, said Kang Soek-Yeon, director of Biopharmaceutica...
Through the main sponsorship of Oscars Viewing Awards, NKCL declared its global marketing to the world. On February 9th, NKCL Bio Group Inc., declared its debut to the global market as the main sponsor of Oscars Viewing Awards, which was held in Hollywood, LA. Shin Donghwa, the Chairman of NKCL Bio G...
NKCL Bio group singing MOU regarding promotion and performing procedure with Suwon Campus Medical Clinic Chairman of NKCL Bio group Shin Dong-Hwa (Left), Director of Campus Medical Clinic Song Yoo-Seok(Right) NKCL Bio Group Inc. (Hereinafter referred to as ‘NKCL Bio Group’) is a bio enterprise that...
NKCL Bio Group Inc. (Hereinafter NKCL Bio Group) received grand award at ‘Promising Brand (Immune Care Platform)’ section in ‘Korea Superb Brand Award 2020’ ceremony, which was hosted by Han-Kyung BUSINESS of Korea Economic Magazine and organized by the Korea Marketing forum on 21th January, 2020...
Chairman of NKCL Bio Group, Shin Dong-Hwa (center left) and the director of Qingdao Orthopaedic Hospital, Dong Xiao-Guang (center right) had signed MOA on 14th January 2020. NKCL Bio Group is a Korean Bio-company that researches NK Immune Cell Treatment using NK cells. Starting with the construction ...
Shin Dong hwa, chairman of NKCL bio Group (second photo, third from left) visited Qingdao Yishengjian General Hospital (first photo) and met the hospital director, Dong Xiaoguang (second picture, second from left) to sign MOA. After NKCL Bio Group has successfully celebrated its construction start ce...
NKCL Bio Group Inc. (hereinafter called ‘NKCL Bio’) held a construction start ceremony for ‘NK Cell GMP Automated Culture System’ in Dongtan New City, Hwaseong, Gyeonggi Province, on December 30th. Chairman Shin Dong-Hwa, giving celebration speech on construction start ceremony of NK Cell GMP Aut...
